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Role of adenosine in the renal responses to contrast medium
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Role of adenosine in the renal responses to contrast medium. Despite
the development of non-ionic radiographic contrast media (CM), CM-
induced nephropathy is a clinically important problem in patients with
pre-existing renal insufficiency. We examined the effects of non-ionic CM
(iohexol) on renal function in conscious dogs with and without renal
insufficiency, and evaluated the effects of a non-selective (theophylline),
an Al selective (KW-3902), and an A2 selective adenosine antagonist
(KF17837) on the renal responses to CM. In sham-operated group,
johexol (2 mI/kg/mm for 3 mm) increased effective renal plasma flow
(ERPF) and glomerular filtration rate (GFR), whereas in renal insuffi-
ciency group (with subtotal nephrectomy), following transient increases in
ERPF and GFR, CM markedly decreased ERPF (—46.5 6.7%) and
GFR (—51.2 7.1%). In sham-operated group, theophylline and
KF17837 markedly attenuated CM-induced increases in ERPF and GFR,
while KW-3902 had no effects on CM-induced increases in ERPF or GFR.
In renal insufficiency group, initial increases in ERPF and GFR were
blunted by theophylline and KF17837. In contrast, the subsequent de-
creases in ERPF and GFR were attenuated by theophylline (%ERPF,
—12.2 3.2% vs. —46.6 6.7%, P < 0.01; %GFR, 4.3 2.5% vs.
—51.0 7.1%, P < 0.01), and were completely prevented by KW-3902(%ERPF, 10.8 2.9%; %GFR, 23.8 4.4%), whereas KF17837
aggravated ERPF (—73.3 5.3%) and GFR (—78.4 5.3%). These data
indicate that in normal renal function, iohexol elicits renal vasodilation by
activating mainly the adenosine A2 receptors. In contrast, in impaired
renal function, CM induces both A2 and Al activation; the former is
associated with the initial renal vasodilation, while the latter is responsible
for the sustained aggravation of renal hemodynamics.
have been conducted to reveal the pathogenesis of CM-induced
nephropathy. It has been shown that theophylline, an adenosine
antagonist, prevents acute renal failure induced by CM in both
animal models [6, 7] and humans [8]. These observations suggest
that the renal protective effects of theophylline are mediated by
the blockade of adenosine action. Theophylline, however, affects
several aspects of vasomotor mechanisms since this agent is a
relatively non-selective adenosine antagonist, and is also reported
to inhibit phosphodiesterase [91.Thus, the precise mechanisms for
theophylline prevention remain undetermined.
In the present study, we examined the effects of non-ionic CM
on renal hemodynamics in dogs with and without pre-existing
renal insufficiency. Furthermore, the effects of a non-selective
adenosine antagonist, theophylline, a newly developed selective
adenosine Al receptor antagonist, 8-(noradamantan-3-yl)- 1,3-
dipropylxanthine (KW-3902) [10—13], and a selective adenosine
A2 receptor antagonist, (E)-1 ,3-dipropyl-8-(3,4-dimethoxystyryl)-
7-methylxanthine (KF17837) [14—17], on CM-induced alterations
in renal function were assessed to characterize the role of
adenosine in mediating the CM-induced renal dysfunction.
Methods
Surgical preparation
A recent development of non-ionic radiographic contrast media
(CM) has contributed to the reduction in the incidence of
CM-induced nephropathy. However, in patients with renal insuf-
ficiency, non-ionic CM fails to reduce the risk of CM-induced
nephropathy [1—3]. Furthermore, clinical necessity for diagnostic
procedures using CM has been increasing, especially in patients
with cardiovascular diseases, whose renal function is frequently
impaired. Despite such clinical demand, there have been no
definitive measures to prevent CM-induced nephropathy.
Previous investigations suggested that renal hemodynamic
changes constituted a determinant of CM-induced nephropathy.
It has been demonstrated that following transient renal vasodila-
tion, CM produces progressive vasoconstriction which conse-
quently causes concomitant decreases in both renal blood flow
and glomerular filtration rate (GFR) [4—6]. Numerous studies
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Male beagles weighing 10 to 12 kg were divided into two
groups: the control group, and the renal insufficiency group. All
surgical procedures were performed under general anesthesia
induced by pentobarbital sodium and maintained with halothane.
Catheters (Tygon, U.S. Stoneware, Akron, OH, USA) were
inserted into the right internal iliac artery and vein, externalized
through the back between the scapulae, and secured. Subse-
quently, in the renal insufficiency group subtotal nephrectomy
(left hemi-nephrectomy and ligation of two of three branches of
the right renal artery) was performed [18, 191; the control group
had a sham operation. Upon completion of surgery, the dogs were
placed in individual cages to allow free mobility. During the
recovery period, all dogs were fed a diet (Oriental Yeast, Tokyo,
Japan) containing 70 mmol sodium and 60 mmol potassium daily.
Free access to tap water was permitted at all times. Serum
creatinine concentration was measured every week. Only the dogs
whose serum creatinine concentration exceeded 1.5 mg/dl had
been included as renal insufficiency group itt the study. All
experiments were performed during 12 to 16 weeks after the
operation.
All hemodynamic studies were performed in conscious dogs
during fasting between 8 a.m. to 3 p.m. in a quiet room, and were
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begun after a 60-minute stabilization period. All procedures were
conducted following the guidelines of the institutional Animal
Care Committee.
Monitoring procedures
The arterial catheter was connected to a pressure transducer
(model TP-400T, Nihon Kohden, Tokyo, Japan) for measurement
of the mean arterial blood pressure (MAP) and heart rate (HR).
The data for MAP and HR were analyzed on a Macintosh
computer, using an analog-digital converter, the Macintosh Lab-
oratory System (MacLab"; Analog Digital Instruments Pty., Ltd.,
Castle Hill, Australia), at a sample rate of 20 points/sec, as
described previously [20—22].
Urine collection and administration of p-aminohippurate (PAH)
and inulin
To assess the renal function including urine flow rate (UFR),
PAH clearance and inulin clearance, 7 Fr. balloon catheters
(Create Medic Co., Yokohama, Japan) were inserted into the
bladder per urethra and urine was collected. Sixty minutes before
starting control measurements, a bolus injection of 20% PAH (80
mg) and 25% inulin (500 mg) was carried out, and PAH (1.2
mg/mm) and inulin (5 mg/mm) at a rate of 0.5 mI/mm were
continuously infused to achieve stable blood levels.
Measurements of plasma renin activity (PRA), hormones, inulin
and PAH
PRA was determined by radioimmunoassay (Dinabott Radio-
isotope, Tokyo, Japan) [23]. Plasma aldosterone concentration
(PAC) was measured by radioimmunoassay (Daiichi Radioiso-
tope, Tokyo, Japan) [24]. PAH and inulin were measured by
colorimetry (Model 7010, Hitachi, Tokyo, Japan).
Study protocol
Experiment 1: Effects of CM on renal function. At 12 to 16 weeks
after surgery, the baseline hemodynamics, including arterial blood
pressure and HR, were measured in dogs with normal renal
function (that is, sham operated; N = 5) and with renal insuffi-
ciency (N = 5) for several consecutive days. All dogs were
prohibited from drinking and eating 24 hours before experiments.
A bolus, followed by a continuous infusion of PAH and inulin
were started, and after a one-hour stabilization period, control
measurements were begun. After 60 minutes of control measure-
ment, iohexol was administered intravenously for 3 minutes; 2
mi/kg/mm for normal renal function, and 1, 2, and 3 mi/kg/mm for
renal insufficiency. Hemodynamic measurements were continued
for two hours after the drug administration, and urine was
collected every 30 minutes. Blood samples were obtained for
measurement of the serum concentrations of creatinine, PAH,
and iriulin at the midpoint of each 30 minutes.
Experiment 2: Effects of adenosine antagonists in normal renal
function. Effects of theophylline (200 jig/kg/mm, i.v. for 150 mm),
KW-3902 (5 jsg/kg/min, i.v. for 150 mm) and KF17837 (10
jig/kg/mm, i.v. for 150 mm) on the renal responses to CM were
investigated in dogs with normal renal function. lohexol (2
mI/kg/mm, i.v. for 3 mm) was administered 30 minutes after
infusion of theophylline (N 5), KW-3902 (N = 5), KF17837(N = 5) or vehicle (see below; N 15). Hemodynamic measure-
ments were continued for two hours after CM administration, and
Table 1. Changes in MAP, renal function, and hormones by
subtotal nephrectomy
Renal
Control insufficiency
MAP mm Hg 75±9 81±5
UFR mi/hr 10±2 9±1
GFRm1/min 26±3 9±P'
ERPF mI/mm 108 14 32 3
PRA ng/mi/hr 1.5 0.3 1.8 0.2
PAC pg/mi 62 7 74 5
Values are means 5EM; N = 5. Abbreviations are: MAP, mean arterial
pressure; UFR, urine flow rate; GFR, glomerular filtration rate; ERPF,
effective renal plasma flow; PRA, plasma renin activity; PAC, plasma
aldosterone Concentration.
a P < 0.01 vs. Control
urine collection and blood sampling were carried out in the same
manner as in the experiment 1. Theophylline was dissolved in
saline, while KW-3902 and KF17837 were dissolved in dimethyl
sulfoxide (DMSO) (100 1.d DMSO for 1 mg KW-3902 and 2 mg
KF17837). DMSO was used as vehicle for KW-3902 and KF17837.
Experiment 3: Effects of adenosine antagonists in renal insuffi-
ciency. Effects of theophylline (200 jtg/kg/min, i.v. for 150 mm),
KW-3902 (5 jig/kg/mm, i.v. for 150 mm) and KF17837 (10
jsg/kg/min, i.v. for 150 mm) on the renal responses to CM were
investigated in dogs with renal insufficiency. lohexol (2 mi/kg/mm,
i.v. for 3 mm) was administered 30 minutes after infusion of
theophyliine (N = 5), KW-3902 (N = 5), KF17837 (N = 5), or
vehicle (N = 15). Hemodynamic measurements were continued
for two hours after CM administration, and urine collection and
blood sampling were carried out in the same manner as in the
experiment 1.
Experiment 4: Effects of calcium antagonist (diltiazem) on CM-
induced renal deterioration. Effects of diitiazem (5 jig/kg/mm, i.v.
for 150 mm) on CM-induced renal deterioration were examined.
Diltiazem (N = 5) or vehicle (N = 5) was injected 30 minutes
before iohexol administration (2 mI/kg/mm, i.v. for 3 mm).
Hemodynamic measurements were continued for two hours after
CM administration. Diltiazem was dissolved in saline.
Materials
lohexol (Omnipaque 300) was purchased from Daiichi Phar-
maceutical Co. Ltd. (Tokyo, Japan). KW-3902 and KF17837 were
gifts from Kyowa Hakko Kogyo Co. Ltd. (Shizuoka, Japan).
Diltiazem was purchased from Sigma Chemical (St. Louis, MO,
USA).
Statistical procedures
Results are expressed as means SCM. Data were analyzed by
one-way or two-way ANOVA as appropriate, followed by Schef-
fe's multiple comparison post hoc test. P < 0.05 was considered
statistically significant.
Results
Effects of subtotal nephrectomy on hemodynamics and hormones
The data of MAP, renal function and hormones in control
group and renal insufficiency group are shown in Table 1. There
were no significant differences in MAP or UFR between two
groups. Both ERPF (clearance of PAH) and GFR (clearance of
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Fig. 1. Effects of iohexol on effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR) in dogs with and without renal insufficiency.
Values are means SEM. Symbols are: (U) Control group, iohexol 2
mI/kg/mm; (III) Renal insufficiency group, iohexol 1 mI/kg/mm; (Li) iohexoi
2 mI/kg/mm; () iohexol 3 mI/kg/mm. *J) < 0.05, < 0.01 vs. baseline,
tP < 0.05, ffP < 0.01 vs. normal renal function.
Time, minutes
lohexol i.v.
Theophylline, KW—3902, KF1 7837 o r vehiclejIi 4 ifç
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Time, minutes
Fig. 2. Effects of theophylline (200 gg/kg/min iv.), KJV-3902 (5 rg/kg/min
iv.) and KF17837 (10 g/kg/min iv.) on renal responses to iohexol (2
mI/kg/mm i. v. for 3 mm) in dogs with normal renal function. Values are
means SEM. Symbols are: (U) CM + vehicle; (Ellhl) CM + theophylline;
(LI) CM + KW-3902; () CM + KF17837. P < 0.05, < 0.01 vs.
baseline, tP < 0.05, ffP < 0.01 vs. vehicle.
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inulin) were markedly decreased in dogs with renal insufficiency.
No differences were noted in PRA or PAC between two groups.
Effects of CM on renal function
In dogs with normal renal function (control), administration of
iohexol (2 mi/kg/mm for 3 mm) markedly increased both ERPF
(52.8 7.3%) and GFR (46.8 6.7%) during 0 to 30 minutes
(Fig. 1). Subsequently, they gradually decreased, but remained
elevated throughout the experimental periods observed.
In dogs with renal insufficiency, a low dose of iohexol (1
ml/kg/min) did not alter ERPF or GFR. A medium dose of
iohexol (2 ml/kg/miri) elicited transient increments in ERPF (36.2
5.6%) and GFR (23.2 4.3%) during 0 to 30 minutes after
injection, followed by significant reductions in ERPF and GFR
during the subsequent 30 to 90 mm (ERPF: 30 to 60 mm, —46.5
6.7%; 60 to 90 mm, —24.3 24.4%; GFR: 30 to 60 mm, —51.2
7.1%; 60 to 90 mm, —12.8 3.3%). A high dose of iohexol (3
mI/kg/mm) decreased ERPF and GFR markedly, and the reduced
renal function persisted throughout the experiment.
Effects of adenosine antagonists in normal renal function
In dogs with normal renal function, the administration of
theophylline, KW-3902 or KF17837 alone did not alter basal
MAP, HR, ERPF or GFR (Fig. 2, Tables 2 and 3).
We used DMSO as solvent for KW-3902 and KF17837, and
saline for theophylline and diltiazem. Since CM-induced renal
hemodynamic changes in the presence of each vehicle did not
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Time after administration N Baseline 45 mm 75 mm
Normal renal function group
MAP mm Hg
theophylline 5 78 6 86 5 84 3
KW-3902 5 74 8 72 5 71 2
KF17837 5 73 5 77 2 79 4
HR beats/mm
theophylline 5 72 6 80 3 79 5
KW-3902 5 77 8 74 5 75 4
KF17837 5 75 5 73 2 74 3
Renal insufficiency group
MAP mm Hg
theophylline 5 79 4 86 5 85 4
KW-3902 5 81 6 83 3 81 2
KF17837 5 83 5 91 4 92 3
diltiazem 5 81 6 83 3 80 5
HR beats/mm
theophylline 5 70 4 77 4 79 3
KW-3902 5 72 5 70 3 71 4
KF17837 5 74 3 76 2 73 4
diltiazem 5 72 5 62 2 58 2
Time after administration N Baseline 30—60 mm 60—90 mm
Normal renal function group
ERPF mi/mm
theophylline 5 110 6 112 5 114 7
KW-3902 5 107 8 110 5 111 6
KF17837 5 107 5 105 7 103 8
GFR mi/mm
theophylline 5 32 6 33 4 34 5
KW-3902 5 33 8 35 7 36 7
KF17837 5 31 5 30 3 28 6
Renal insufficiency group
ERPF mi/mm
theophylline 5 34 4 36 3 35 4
KW-3902 5 32 3 33 5 33 2
KF17837 5 30 5 31 4 30 3
diltiazem 5 32 3 35 5 34 5
GFR mi/mm
theophylline 5 10 2 10 2 9 2
KW-3902 5 9±1 9±2 10±2
KF17837 5 9±1 9±2 8±2
diltiazem 5 9 1 10 1 10 I
differ, the results obtained from each vehicle study were incorpo-
rated into a single set of data and were depicted as "CM +
vehicle" in Figures 2 to 4.
Theophylline markedly altered the CM-induced responses of
ERPF and GFR. Thus, the CM-induced increases in ERPF were
prominently diminished (0 to 30 mm, 8.0 2.8%; 30 to 60 mm, 1.0
1.6%; 60 to 90 mm, 0.8 1.4%), as compared with those in the
absence of theophylline (0 to 30 mm, 53.1 7.3%, P < 0.01; 30
lohexol Lv.
lohexol i.v.
Fig. 3. Effects of theophylline (200 pg/kg/mm i.v.), KW-3902 (5 pg/kg/mm
iv.) and KF17837 (10 pg/kg/mm iv.) on renal responses to iohexol (2
mi/kg/mm i.v. for 3 mm) in dogs with renal insufficiency. Values are means
SEM. Symbols are: (•) CM + vehicle; (1111) CM + theophylline; (ED CM
+ KW-3902; () CM + KF17837. *p < 0.05, < 0.01 vs. baseline, tP
< 0.05, ftP < 0.01 vs. vehicle.
to 60 mm, 24.0 4.4%, P < 0.01; 60 to 90 mm, 9.0 2.9%, P <
0.05). Similarly, theophylline prominently suppressed the iohexol-
induced increments in GFR (0 to 30 mm, 6.3 2.6% vs. 46.7
6.7%, P < 0.01; 30 to 60 mm, 3.9 2.4% vs. 21.9 4.2%, P <
0.05; 60 to 90 mm, 2.9 2.3% vs. 16.0 3.6%, P < 0.05, for
theophylline and vehicle, respectively).
The pretreatment with KW-3902 failed to alter the iohexol-
induced responses of ERPF throughout the experimental periods.
Similarly, KW-3902 had no effects on the increments in GFR
induced by iohexol.
In contrast to the effects of KW-3902, the pretreatment with
KFI 7837 prominently blunted the CM-induced increases in both
ERPF and GFR. Thus, the iohexol-induced initial (that is, 0 to 30
Table 2. Effects of theophylline, KW-3902, KF17837 or diltiazem on
MAP and HR
Theophylline, KW—3902, KF1 7837 or vehicle
—30—0 0—30 30—60 60—90 90—120
Values are means SEM. Abbreviations are: MAP, mean arterial
pressure; HR, heart rate, theophylline 200 jrglkglmin i.v.; KW-3902 5
/Lg/kg/min i.v.; KF17837 10 /Lg/kg/min iv.; diltiazem 5 /Lg/kg/min iv.
P < 0.05 vs. baseline
Table 3. Effects of theophylline, KW-3902, KF17837 or diltiazem on
ERPF and GFR
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*ktt
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Time, minutes
Values are means SEM. Abbreviations are: ERPF, effective renal
plasma flow; GFR, glomerular filtration rate; theophylline 200 jzg/kg/min
iv.; KW-3902 5 jrg/kg/min iv.; KF17837 10 pg/kg/mm iv.; diltiazem 5
pg/kg/mm iv.
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mm) increases in ERPF and GFR were markedly diminished
(14.8 3.5% and 11.2 3,1%, respectively), as compared with
those in the absence of KFI 7837 (52.9 7.3%, P < 0.01 and 46.5
6.7%, P < 0.01, respectively). Furthermore, KF17837 pre-
vented the subsequent iohexol-induced increments in ERPF (30
to 60 mm, —1.7 2.2%; 60 to 90 mm, —1.2 2.1%). In analogy,
iohexol failed to increase GFR in the presence of KF17837 (30 to
60 mm, —6,9 2.7%; 60 to 90 mm, —5.2 2.5%; 90 to 120 mm,
—2.4 2.2%).
Effects of adenosine antagonists in renal insufficiency
In dogs with renal insufficiency, the administration of theophyl-
line, KW-3902 or KF17837 alone had no effects on MAP, HR,
ERPF or GFR (Fig. 3, Tables 2 and 3).
The pretreatment with theophylline suppressed both the initial
increments and the subsequent decrements in ERPF. Thus, in the
presence of theophylline, iohexol failed to alter ERPF during 0 to
30 minutes (4.1 2.4%), and the CM-induced reductions in
ERPF were attenuated during 30 to 90 minute (30 to 60 mm,
—12.2 3.2%; 60 to 90 mm, —7.6 2.8%), as compared with
marked declines in the absence of theophylline (30 to 60 mm,
—46.6 6.7%, P < 0.01; 60 to 90 mm, —24.5 4.4%, P < 0.05).
Similarly, theophylline attenuated the iohexol-induced initial in-
crements in GFR observed during 0 to 30 minutes (4.6 2.5% vs.
23.2 4.3%, P < 0.01). Furthermore, reductions in GFR were
completely abolished by theophylline (30 to 60 mm, 4.3 2.5% vs.
—51.0 7.1%, P < 0.01; 60 to 90 mm, 3.6 2.4% vs. —12.9
3.3%, P < 0.01; for theophylline and vehicle, respectively).
KW-3902 not only prevented CM-induced renal deterioration,
but actually maintained ERPF and GFR above baseline levels.
Thus, ERPF increased during 0 to 30 minutes (35.8 5.6%), and
the increases in ERPF persisted throughout the experimental
periods (30 to 60 mm, 10.8 2.9%; 60 to 90 mm, 15.4 3.2%; 90
to 120 mm, 13.2 3.2%), as compared with marked declines in
the absence of KW-3902 (30 to 60 mm, —46.5 6.7%, P < 0.01;
60 to 90 mm, —24.3 4.4%, P < 0.01; 90 to 120 mm, —3.8
2.4%, P < 0.01). Similarly, KW-3902 enhanced the iohexol-
induced initial increments in GFR during 0 to 30 minutes (43.8
6.4% vs. 23.0 4.3%, P < 0.05). Furthermore, in contrast to
marked reductions in GFR in the absence of KW-3902 (30 to 60
mm, —50.8 7.1%; 60 to 90 mm, —12.9 3.3%; 90 to 120 mm,
—4.8 2.5%), GFR remained elevated throughout the experi-
mental periods (30 to 60 mm, 23.8 4.4%; 60 to 90 mm, 32.0
4.2%; 90 to 120 mm, 25.6 4.6%).
KF17837 not only blunted the CM-induced rise in renal func-
tion but also aggravated the CM-induced renal dysfunction. Thus,
KF17837 abolished the CM-induced initial increment in ERPF
(that is, 3.2 1.7% vs. 35.8 5.6%, P < 0.01). Furthermore, in
the presence of KF17837, the CM-induced reductions in ERPF
were markedly enhanced (that is, 30 to 60 mm, —73.3 5.3%; 60
to 90 mm, —44.7 4.0%; 90 to 120 mm, —22.5 3.2%), as
compared with those in the absence of KF17837 (30 to 60 mm,
—46.5 6.7%, P < 0.05; 60 to 90 mm, —24.3 4.4%, P < 0.05;
90 to 120 mm, —3.8 2.4%, P < 0.01). In analogy, KF17837
abolished the iohexol-induced initial increments in GFR during 0
to 30 mm (—9.1 2.9% vs. 23.0 4.3%, P < 0.01). Furthermore,
KFI 7837 aggravated the CM-induced declines in GFR (30 to 60
mm, —78.4 5.3% vs. —50.8 7.1%, P < 0.05; 60 to 90 mm,
—44.5 5.5% vs. —12.9 3.3%, P < 0.01; 90 to 120 mm, —32.0
4.2% vs. —4.8 2.5%, P < 0.01).
Effects of calcium antagonist (diltiazem) on CM-induced
renal deterioration
The effects of diltiazem on CM-induced renal deterioration
were assessed in dogs with renal insufficiency, and were compared
with those of KW-3902 (Fig. 4).
The dose of diltiazem used in the experiment did not alter basal
MAP, ERPF or GFR, while modestly decreased HR (Tables 2
and 3).
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Fig. 4. Effects of KW-3902 (5 pg/kg/mm iv.) and diltiazem (5 p.g/kg/mmn
iv.) on declines in effective renal plasma flow (ERPF) and glomerular
filtration rate (GFR) induced by iohexol (2 ml/kg/min i.v. for 3 mm) in dogs
with renal insufficiency. Values are means SEM. Symbols are: (•) CM +
vehicle; (11111) CM + KW-3902; (LI) CM + diltiazem. < 0.05, 44P < 0.01
vs. baseline, tP < 0.05, ffP < 0.01 vs. vehicle.
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Diltiazem completely prevented the CM-induced reductions in
ERPF and GFR. Thus, ERPF was increased during 0 to 30
minutes after CM administration (36.2 5.6%), and the increases
in ERPF persisted throughout the experimental periods (30 to 60
mm, 20.3 4.0%; 60 to 90 mm, 23.6 4.4%, 90 to 120 mm, 25.7
4.6%); the increments in ERPF were nearly identical in
magnitude with those in the presence of KW-3902. Similarly, in
the presence of diltiazem, the CM-induced increase in GFR (that
is, 32.1 5.1% at 0 to 30 mm) was maintained above pre-CM
level throughout the study (30 to 60 mm, 28.1 4.3%; 60 to 90
mm, 25.9 4.7%; 90 to 120 mm, 22.7 4.2%).
Discussion
In the present study, we have demonstrated that in dogs with
normal renal function, a non-ionic CM, iohexol, causes sustained
increases ERPF and GFR. In striking contrast, in dogs with
pre-existing renal insufficiency, following transient increments in
ERPF and GFR, CM deteriorates prominently the renal hemo-
dynamics. Furthermore, administration of a non-selective adeno-
sine antagonist, theophylline, and a selective adenosine A2 recep-
tor antagonist, KF17837, markedly attenuate the CM-induced
increases in ERPF and GFR both in normal and in impaired renal
function. Additionally, in dogs with renal insufficiency, the CM-
induced renal deterioration was prevented by theophylline, a
selective Al receptor antagonist (KW-3902), and a calcium an-
tagonist (diltiazem). Thus, the present study demonstrates that
adenosine plays an important role in CM-induced deterioration of
renal insufficiency. Furthermore, multiple vasoregulatory mecha-
nisms contribute to the CM-induced alterations in renal hemody-
namics; the CM-induced vasoconstriction is mediated by adeno-
sine Al receptors and the subsequent calcium influx through
voltage-operated calcium channels, whereas adenosine A2 recep-
tors are responsible for the CM-induced renal vasodilation.
Contribution of non-ionic CM to reducing the incidence of
acute renal failure remains to be determined. Initially, the intro-
duction of non-ionic CM was expected to reduce the incidence of
CM-induced nephropathy, based on the results observed in
animals with normal renal function [25, 26]. The subsequent
clinical investigations, however, failed to demonstrate a less
nephrotoxicity of non-ionic CM in patients with renal insufficiency
[1—31. It appears, therefore, that the risk of non-ionic CM-induced
nephropathy depends on the pre-existing renal insufficiency.
To confirm whether pre-existing renal insufficiency contributes
to the development of non-ionic CM-induced nephropathy, we
examined the effects of non-ionic CM on renal function in dogs
with and without renal insufficiency. Thus, the present study has
demonstrated that after only transient increases in ERPF and
GFR, iohexol produces marked reductions in ERPF and GFR in
renal insufficiency dogs. In contrast, in dogs with normal renal
function, iohexol elicited prominent increases in ERPF and GFR,
and they remained elevated throughout the study. Sustained
deterioration in renal hemodynamics, observed only in the setting
of renal insufficiency, could therefore constitute a critical deter-
minant of the development of CM-induced ARF.
Although the precise mechanisms of CM-induced deterioration
of renal function remain undetermined, several investigations
have suggested that adenosine mediates CM-induced renal vaso-
constriction [6, 71. Thus, theophylline, a non-selective adenosine
antagonist, markedly inhibited the CM-induced renal vasocon-
striction [61. Furthermore, the administration of theophylline
prevented the renal deterioration in patients with renal failure [8].
In the present study, we have demonstrated that both non-
selective (that is, theophylline) and Al-selective adenosine recep-
tor antagonists (KW-3902) markedly prevent CM-induced deteri-
oration in renal function in dogs with renal insufficiency.
Additionally, infusion of adenosine is reported to elicit marked
decreases in renal blood flow [27—29]. In concert, these observa-
tions strongly suggest that intrarenally-formed adenosine is in-
volved in the development of CM-induced renal deterioration,
which may lead to acute renal failure.
Several lines of recent investigations have clarified that adeno-
sine acts at least via two different receptor subtypes. Of these,
adenosine Al receptors are associated with vasoconstriction. With
respect to renal hemodynamics, adenosine Al receptor agonists
[30, 311 are reported to cause renal vasoconstriction. Thus, in the
setting under which adenosine is responsible for the renal dete-
rioration, the blockade of adenosine Al receptors would amelio-
rate the renal dysfunction. In the present study, we have demon-
strated that a novel, potent and selective adenosine Al receptor
antagonist, KW-3902 [10—13], completely prevents the CM-in-
duced aggravation of renal function in dogs with renal insuffi-
ciency; rather, CM-induced increments in ERPF and GFR were
maintained elevated throughout the experimental periods in the
presence of KW-3902 (Fig. 3). In contrast, KW-3902 alone had no
effects on renal hemodynamics (Table 3). Collectively, our present
findings indicate that adenosine Al-related renal vasoconstriction
is involved in the CM-induced deterioration of renal insufficiency.
We propose that the detrimental effects of CM are mediated by
adenosine Al receptors.
The present study has demonstrated that theophylline not only
prevents the CM-induced deterioration in renal hemodynamics in
renal insufficiency, but also attenuates the increases in ERPF and
GFR in both normal and impaired renal function. The latter
observations indicate that adenosine participates in the CM-
induced increases in renal hemodynamics. In this regard, adeno-
sine causes vasodilation mediated by adenosine A2 receptor
subtypes in most vascular beds [32—34]. In the renal vasculature, it
has been demonstrated that adenosine A2 agonists elicit renal
vasodilation [35, 36]. The present study shows that KF17837, a
selective adenosine A2 antagonist, attenuates the CM-induced
increments in ERPF and GFR in both normal and impaired renal
function, and aggravates the CM-induced renal deterioration in
renal insufficiency (Fig. 3). In concert, these observations indicate
that adenosine A2 receptor-mediated vasodilation contributes to
the CM-induced increases in renal hemodynamics in normal renal
function, and also counters the adenosine Al-mediated renal
aggravation in impaired renal function.
Of note, in dogs with normal renal function, the blockade of
adenosine A2 receptors by KF17837 almost completely abolished
the CM-induced responses, whereas blocking Al receptors by
KW-3902 had only modest effects on renal hemodynamics. These
findings suggest that adenosine A2 receptor-mediated renal vas-
cular responses constitute a major determinant of CM-induced
alterations in renal hemodynamics under normal renal function.
In striking contrast, in dogs with renal insufficiency, adenosine Al
blockade converted the CM-induced decreases to the increases in
both ERPF and GFR, indicating a predominant role of adenosine
Al receptors in mediating the CM-induced renal responses. It
appears, therefore, that the relative contribution of adenosine Al
and A2 receptors to CM-induced renal responses may be altered
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in renal insufficiency, and the exaggerated Al subtype-linked
renal responses could account for the CM-induced exaggerated
deterioration in renal hemodynamics in impaired renal function.
The preferential activation of adenosine Al receptors and the
subsequent renal vasoconstriction by CM in renal insufficiency
might indicate that selective adenosine Al antagonists, devoid of
antagonism of vasodilatory adenosine Al receptors, are prefera-
ble for the protection of renal function from CM-induced renal
deterioration.
It has been suggested that calcium ion plays an important role
in CM-induced renal dysfunction and in mediating the adenosine-
induced renal vasoconstriction. The present study indicates that
adenosine Al receptors are involved in the CM-induced renal
hemodynamic changes. Furthermore, activation of adenosine Al
receptors is associated with a decrease in cAMP, which could
subsequently alter the activity of voltage-operated calcium chan-
nels [37—391. Thus, adenosine-induced renal vasoconstriction is
reported to be inhibited by blocking voltage-operated calcium
channels [37, 39]. In concert, these observations allow one to
speculate that CM-induced renal vasoconstriction is linked to
voltage-operated calcium channels. Indeed, our present finding
and the reports from other laboratories [6, 40] have demonstrated
that CM-induced renal vasoconstriction is blocked by voltage-
operated calcium channels. CM-induced renal vasoconstriction is,
therefore, mediated by a central common vasoconstrictor mech-
anism, that is, calcium entry through voltage-operated calcium
channels.
In conclusion, we have demonstrated that in dogs with normal
renal function, non-ionic CM, iohexol, causes prominent vasodi-
lation, mediated by adenosine A2 receptors. In contrast, in dogs
with renal insufficiency, the CM induces a transient renal vasodi-
lation, followed by a sustained and profound vasoconstriction.
The initial vasodilation is mediated by adenosine A2, and the
sustained vasoconstriction by adenosine Al receptor-linked re-
sponses. Furthermore, a calcium antagonist, diltiazem, inhibits
the CM-induced aggravation in renal hemodynamics, suggesting
that voltage-operated calcium channels mediate the CM-induced
renal dysfunction as a common vasoconstrictor pathway. The
present study indicates a major role for adenosine in the devel-
opment of non-ionic CM-induced renal deterioration. The alter-
ations in relative contribution of adenosine Al and A2 receptor
subtypes to CM-induced renal responses may be responsible for
the divergent renal hemodynamic responses observed in normal
and impaired renal function. The predominant adenosine Al
activation by CM in renal insufficiency could increase the suscep-
tibility of the kidney with impaired function to contrast media.
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